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Background
HIV vaccines that induce mucosal immunity are urgently
needed. Common mucosal compartments enable vac-
cines to be administered to the upper respiratory tract for
concomitant immunity in the vagina and rectum. We
investigated the potential of recombinant influenza as a
live-attenuated vaccine to induce SIV-specific T cell immu-
nity in a non-human primate model of HIV infection.
Methods
Recombinant H1N1 and H3N2 influenza A strains were
engineered to express SIV CD8 T cell epitopes and evalu-
ated for their capacity to induce primary and booster
responses following administration to the respiratory tract
of Pig-tail macaques. Two naïve macaques and eight SIV
infected macaques were vaccinated with two doses of
H1N1-expressing SIV KP9 followed by two doses of
H3N2-expressing SIV KP9 or vice-versa and evaluated for
influenza infection, SIV epitope-specific and influenza-
specific T cell responses. Naïve macaques were subse-
quently challenged with SIVmac251. Three influenza
viruses expressing different SIV CD8 epitopes were also
evaluated.
Results
Influenza infection was asymptomatic however macaques
seroconverted, generated T cell responses to influenza
proteins and virus was detected in the respiratory tract. SIV
KP9-specific CD8 T cell responses were primed in naive
animals and a proportion expressed the mucosal homing
marker β7 integrin. SIV challenge resulted in a large anam-
nestic recall CD8 T cell response but immune escape rap-
idly ensued and there was no impact on chronic SIV
viremia. Vaccination of SIV infected macaques resulted in
the boosting of existing KP9 responses. Sequential vacci-
nation with different influenza strains produced only a
limited boost in immunity, probably reflecting T cell
immunity to internal influenza proteins. Vaccinating with
multiple SIV epitopes augmented responses to each
epitope.
Conclusion
These results augur well for the development of influenza
to deliver HIV antigens. Broader antigen cover will be
needed to limit CTL escape. We are now developing con-
structs which express whole SIV proteins.
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